Ametris - formerly ActiGraph

09/25/2025

📈 Are you currently using digital health technology in your research? Don't miss your opportunity to discuss your project with key thought leaders in the digital health field!

The poster session is designed to give researchers the chance to share their original research involving use of DHTs, discuss the details of their project, and network with their colleagues 🤝

📥 We invite you to submit your abstract to the Scientific Poster Session at ADDS Atlanta 2026 by October 31st, 2025.

Follow the link in the comments to review the submission criteria and submit your abstract! ⤵️

09/23/2025

🚨 Despite extensive effort, many late-stage ALS trials have failed to meet their primary endpoints, reflecting not only the complexity of the disease, but also the limitations of traditional outcome measures.

Join us for the next session of Digital Health Monthly: Redefining ALS Clinical Endpoints: Unlocking the Potential of Digital Health Technologies. Registration link is in the comments ⤵️

In this discussion, we’ll bring together multidisciplinary stakeholders to explore -

🔎 The limitations of traditional endpoints such as ALSFRS-R and survival

🔎 How digital health technologies can can complement traditional outcome measures to provide more sensitive measures across multiple modalities, including physical function, sleep, respiratory function, speech, and cognitive performance

🔎 How we can reach consensus on standardized measures to ensure scientific credibility and real-world impact of digital endpoints in ALS clinical trials

Featured Speakers -
🔺Adam LaPrad, PhD, Head of Product and Scientific Affairs, ZEPHYRx
🔺David Suendermann-Oeft, Chief Executive Officer, Modality AI
🔺Collin Hovinga, PharmD, M.S., FCCP, Vice President of Rare and Orphan Diseases, Critical Path Institute
🔺Dr. Nadia Sethi, Founder, Patient Advocate, North Star ALS
🔺Rakesh Pilkar, PhD, Lead of DHT Solutions Neuroscience, Ametris (formerly ActiGraph)

ALS remains a devastating, incurable disease with urgent need for innovation. By collaborating across the ecosystem, we can bring forward credible, scalable, and meaningful measures that support the next generation of treatments.

09/22/2025

You can now watch last week's Digital Health Monthly webinar on-demand to learn about the goals and workstreams of DECODE Obesity!

🔗 to watch is in the comment below ⤵️

Discover how a collaborative consortium approach can tackle key challenges in advancing digital measures for regulated clinical trials, and learn about the specifics DECODE Obesity consortium.

Our panelists from Eli Lilly and Company, F. Hoffman La Roche, and Novo Nordisk discussed the motivation for joining the consortium and the benefits of digital measures in this area, including -

📘 The multifaceted applications of objective, continuous data to inform efficacy evaluation, trial design, and program decision making
📘 The value of real-world measures of participant function and physiology to inform a holistic view of health
📘 Regulators can be more receptive to this type of collaborative approach
📘 Access to an annotated, high-quality digital data set

Thank you Faisal Khan, Brian Winger, Jonas Dorn, and Sylvain Zorman for joining and leading an interesting and engaging discussion on this important topic!

🤝 The DECODE Obesity working group is accepting additional pharmaceutical industry partners. Visit the DECODE Obesity webpage (linked below) to learn more and to contact us if you are interested!

09/16/2025

📣 Register today for our Digital Health Monthly webinar THIS THURSDAY, 9/18, to hear more details about the workstreams and goals of the DECODE Obesity working group!

We'll hear from working group members who will discuss -
➡️ why they joined DECODE Obesity
➡️ what is needed for DHTs to reach full utility in clinical trials
➡️ the pros and cons of different approaches to developing and validating DHTs for use in clinical development

Featured Speakers -
🔹Faisal Khan, PhD, CVP AI & Analytics, Data Science, Novo Nordisk
🔹Brian E. Winger, PhD, Associate VP, Digital Health, Portfolio Owner and Device Engineering Leader, Eli Lilly
🔹Jonas Dorn, PhD, Digital Biomarker Technology Lead, F. Hoffman La Roche
🔹Sylvain Zorman, PhD, Director DHT Solutions Strategy, Ametris

Registration link is in the comments 👇

09/09/2025

📰 Did you hear the news? Last week, we announced the launch of DECODE Obesity!

This cross-industry collaboration between founding partners Eli Lilly and Company, F. Hoffman La Roche, Novo Nordisk and Ametris will focus on evidence generation and regulatory engagement to enhance clinical programs in obesity with mature assessments of physical activity and function.

📆 Please join us for a Digital Health Monthly webinar on Thursday, September 18th at 12PM ET to hear more details about the workstreams and goals of the DECODE Obesity working group!

Featured speakers -
🔸Faisal Khan, PhD, CVP AI & Analytics, Data Science, Novo Nordisk
🔸Brian E. Winger, PhD, Associate VP, Digital Health, Portfolio Owner and Device Engineering Leader, Eli Lilly
🔸Jonas Dorn, PhD, Digital Biomarker Technology Lead, F. Hoffman La Roche
🔸Sylvain Zorman, PhD, Director DHT Solutions Strategy, Ametris

Register today using the link in the comments ⤵️

09/08/2025

📣 Call for Abstracts! 📣 Come share your DHT research at ADDS Atlanta 2026!

While can't wait to connect with the digital health community in Europe this week at ADDS Basel 2025, we are already planning for the next opportunity to bring digital health leaders together at on February 23 - 25!

🗓️ We invite you to submit your abstract for consideration to be included in the Scientific Poster Session no later than Friday, October 31st, 2025.

⤵️ Follow the link below to submit your abstract and join us to accelerate the adoption of DHTs in clinical research.

09/05/2025

💭 Are you interested to learn about the latest DHT applications in clinical research?

💭 Do you want to connect with leaders in the digital health field to better understand how DHT could advance your work?

❗ Join us on September 12th at ADDS Basel 2025. This unique event brings together the multidisciplinary digital health field to share case studies, lessons learned, and best practices to accelerate the adoption of DHTs in clinical research.

Don't miss the opportunity to learn from and network with this diverse group of professionals in the digital health community.

View our agenda - featuring 4 sessions across the topics of , , and - and register to attend using the link in the comments ⤵️

09/03/2025

📨 This is your invitation to join the next Digital Health Monthly Webinar - DECODE Obesity: Advancing Digital Endpoints for the Next Generation of Treatments

🔓 GLP-1 treatments have reshaped the future of obesity drug development, unlocking new levels of efficacy and broadening applications across multiple indications. But with these advances comes a new challenge: demonstrating treatment benefits beyond weight loss to optimize program success, differentiate therapies, and strengthen payer negotiations.

That’s why (formerly ActiGraph), together with founding partners Eli Lilly, F. Hoffman La Roche, and Novo Nordisk, launched DECODE Obesity - a cross-industry initiative to accelerate the development and validation of digital endpoints in obesity.

During the webinar, we will -
🔹 Share DECODE Obesity’s mission, workstreams, and goals
🔹 Hear directly from working group members on why they joined the initiative
🔹 Explore what’s needed for DHTs to achieve full utility in clinical trials
🔹 Discuss the opportunities and challenges in validating DHTs for obesity research

Featured panelists -
🔸Faisal Khan, PhD, CVP AI & Analytics, Data Science, Novo Nordisk
🔸Brian E. Winger, PhD, Associate VP, Digital Health, Portfolio Owner and Device Engineering Leader, Eli Lilly
🔸Jonas Dorn, PhD, Digital Biomarker Technology Lead, F. Hoffman La Roche
🔸Sylvain Zorman, PhD, Director DHT Solutions Strategy, Ametris

⤵️ Don’t miss the chance to learn how this collaboration is shaping the future of obesity clinical development. Register using the link in the comments!

09/02/2025

📣 We are excited to announce our next Digital Endpoint Collaboration to accelerate Outcome DEvelopment working group – DECODE Obesity!

Led by , DECODE Obesity is a cross-industry collaboration including initial pharmaceutical company partners Eli Lilly and Company, F. Hoffmann La Roche, and Novo Nordisk. Read the full announcement: https://hubs.la/Q03GtSY20

🔍 The working group will focus on evidence generation and regulatory engagement to enhance clinical programs in obesity with mature assessments of physical activity and function using wearable DHTs.

Why is this important? Continuous and real-life measures of these important covariates and additional clinically meaningful outcome measures can help assess efficacy of new obesity treatments.

➡️ Is your team investigating new therapies for obesity? The DECODE Obesity working group is currently accepting additional collaborators! For more information, visit the DECODE Obesity webpage: https://hubs.la/Q03GtV7z0

This collaboration will focus on evidence generation and regulatory engagement to enhance clinical programs in obesity with mature assessments of physical activity and function.

09/01/2025

↪️ ADDS Basel 2025 is right around the corner! Have you secured your ticket?

🧐 Review the ADDS Basel 2025 agenda to see the scientific presentations, case studies, and panel discussions we have scheduled across four main session topics - Oncology, Neurology, Technical Validation, and Regulatory Pathways - aimed to accelerate the adoption of DHTs in regulated trials.

Plus, scheduled networking breaks and the Scientific Poster Session give attendees the chance to engage with their colleagues and foster opportunities for future collaboration. 🤝

Spots are filling up! Reserve your ticket and register today using the link in the comments! ⤵️

08/27/2025

📈 Continuous sensor data from digital health technologies enable remote, real-world, and objective data capture in clinical trials -

✅ This type of data often provides more sensitive measures for important insights to assess treatment efficacy, differentiate assets, and demonstrate patient-centric benefits.

However, DHT data can be more complex than traditional measures, and it can be difficult to know where to begin. 🤔

The answer❓Begin with the end in mind!

📝 Clearly defining the context of use helps sponsors collect the proper evidence packages to support that use and can facilitate interactions with regulators.

Download our eBook focusing on the use of wearable data for supporting efficacy endpoints for more strategic recommendations and key considerations to successfully integrate wearable DHTs and fully realize the benefits they can bring to your study 👇

08/26/2025

📊 The Scientific Poster Session is always a highlight of each ADDS conference, and our poster line-up for the ADDS Basel 2025 session is exceptional!

From studies investigating how adolescent movement profiles provide insight into later depressive symptoms to smartwatch adherence in a multi-year Huntington's Disease study, attendees will have the chance to discuss this cutting-edge DHT research with our poster presenters.

There is still time to reserve your registration and join us on September 12th!

Check out the full list of poster titles and register today for ADDS Basel 2025 using the link below ⤵️

👏 Thank you to all our poster presenters who will share your work with us at ! Chris Knowles, Zeynep Gultung Aydemir, Anastasia Ilina, Jelle de Jong, Arvind Ramanujam, Marcelo Stegmann, Katarzyna Wac, Marcin Straczkiewicz, Yann Le Guillou, Oscar Reyes, Michael Neumann, Ayla Durrer, Dominik Kunz, Claire Lugrin